DECRYPTION – A clinical trial shows the benefits of combining immunotherapy and chemotherapy against this cancer which occurs half of the time before the age of 35. But the American experience will not be directly applicable to France, because the reference protocol is different.
For American doctors, it is a “practice changing” study: its results, published Wednesday in The New England Journal of Medicineshould lead to a change in the treatment protocol for Hodgkin lymphoma in the United States. This cancer of the lymphatic system is quite rare, but it affects many young people – half of patients are under 35 years old.
« While the diagnosis was a death sentence in the 1960s, the lymphoma hodgkinian is taking good care of himself today »notes the Dr Jonathan Friedberg, director of the Wilmot Cancer Center at the University of Rochester, who coordinated the clinical trial published Wednesday. Sensitive to chemotherapy and radiotherapy, it is cured in more than 80% of cases (and even 90% before the age of 20). « But drugs, especially those administered in aggressive presentations or at an advanced stage, are extremely…
This article is reserved for subscribers. You have 83% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
France
Health
